Previous 10 | Next 10 |
BioLineRx Ltd. (BLRX) Q4 2018 Earnings Conference Call March 27, 2019, 10:00 AM ET Company Participants Tim McCarthy - LifeSci Advisors, IR Phil Serlin - CEO Mali Zeevi - CFO Abi Vainstein - VP, Clinical and Medical Affairs Ella Sorani - VP, Research and Development Confer...
biolinerx (NASDAQ: BLRX ): FY GAAP EPS of -$0.21. More news on: BioLineRx Ltd., Earnings news and commentary, Healthcare stocks news, , Read more ...
TEL AVIV, Israel , March 28, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, today reports its financial results for the year ended December 31, 2018 and provided a corporate update. Highlights and achie...
CORAL GABLES, FL / ACCESSWIRE / March 27, 2019 / The tech stock market has been anything but quiet in the first few months of 2019. Companies across the tech industry are pulling out all the stops to allocate resources for the development of innovative technology. Nowadays, consumers are o...
BioLineRx (NASDAQ: BLRX ) reports that hematopoietic stem cells (HSCs) mobilized by BL-8040 in combination with granulocyte colony-stimulating factor (G-CSF) were successfully engrafted in all 11 patients participating in the Part 1, lead-in period of the GENESIS Phase 3 trial. ...
TEL AVIV, Israel , March 27, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE:BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that hematopoietic stem cells (HSCs) mobilized by BL-8040 in combination with granulocyte colony-stimulating...
TEL AVIV, Israel , March 21, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today it will release its audited annual financial results for the year ended December 31, 2018 ...
TEL AVIV, Israel , March 14, 2019 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that its Chief Executive Officer, Philip Serlin , will present a company update at the 29th Annual Oppenhe...
BioLineRx Announces Closing of $15.4 Million Underwritten Public Offering of its American Depositary Shares and Warrants Canada NewsWire TEL AVIV, Israel, Feb. 7, 2019 TEL AVIV , Israel , Feb. 7, 2019 /CNW/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical...
At Phase 3 of development, expecting to have $55 million in cash after the sale of warrants and with very little debt, BioLineRx (BLRX) is interesting. In addition, the company trades with an enterprise value of only $12 million, which seems very small. Other competitors at a similar stage of ...
News, Short Squeeze, Breakout and More Instantly...
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD) PR Newswire - Investigator-initiated study in...
Orkla ASA ADR (ORKLY) is expected to report for Q1 2024 Cosmos Health Inc. (COSM) is expected to report $-0.14 for Q1 2024 Basilea Pharmaceutica AG Registered Shares (BPMUF) is expected to report for Q1 2024 DCC Plc (DCCPF) is expected to report for Q4 2024 Datatec Ltd ADR (DTTLY)...
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting PR Newswire New analysis of biopsy samples demonstrate...